Dr. Gutierrez on Biomarker-Directed Precision Oncology of Pembrolizumab-Based Combos in NSCLC
Martin E. Gutierrez, MD, discusses the biomarker-directed precision oncology of pembrolizumab-based combination therapy in the treatment of patients with non–small cell lung cancer.